Free Online CME

Mastering the Treatment of Myeloid
Malignancies in the Era of Personalized
Medicine

Print this Content

Description

Mastering the Treatment of Myeloid Malignancies in the Era of Personalized Medicine online series will provide an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with myeloid malignancies.

Webcasts

ASH Symposium
Release date: January 22, 2021
Expiration date: January 22, 2023
Estimated Time: 30 minutes
Type:  Webcast
Technical Requirements: None
Specialty: Hematology/Oncology
ASH Symposium
Release date: January 22, 2021
Expiration date: January 22, 2023
Estimated Time: 30 minutes
Type:  Webcast
Technical Requirements: None
Specialty: Hematology/Oncology
ASH Symposium
Release date: January 22, 2021
Expiration date: January 22, 2023
Estimated Time: 30 minutes
Type:  Webcast
Technical Requirements: None
Specialty: Hematology/Oncology
ASH Symposium
Release date: January 22, 2021
Expiration date: January 22, 2023
Estimated Time: 30 minutes
Type:  Webcast
Technical Requirements: None
Specialty: Hematology/Oncology
ASH Symposium
Release date: January 22, 2021
Expiration date: January 22, 2023
Estimated Time: 15 minutes
Type:  Webcast
Technical Requirements: None
Specialty: Hematology/Oncology
ASH Symposium
Release date: January 22, 2021
Expiration date: January 22, 2023
Estimated Time: 30 minutes
Type:  Webcast
Technical Requirements: None
Specialty: Hematology/Oncology
ASH Symposium
Mastering the Treatment of Myeloid Malignancies in the Era of Personalized Medicine Case-Based Panel Discussion
Kelly Bolton, MD, PhD, Vikas Gupta, MD, FRCP, FRCPath, Betty Hamilton, MD, Jeffrey E. Lancet, MD, Jaroslaw Maciejewski, MD, PhD, Guillermo Sanz, MD, PhD
Release date: January 25, 2021
Expiration date: January 25, 2023
Estimated Time: 30 minutes
Type:  Webcast
Technical Requirements: None
Specialty: Hematology/Oncology

Series Learning Objectives

  • Formulate appropriate evaluation and management strategies for patients with aplastic anemia and other bone marrow failures.
  • Define the specific indications for targeted therapies in patients with acute myeloid leukemia (AML), concept of minimal residual disease in AML, and management strategies for adverse events related to novel therapies.
  • Critically review the emerging treatment strategies for patients with low-risk and high-risk myelodysplastic syndromes.
  • List the pharmacologic profiles, efficacy and side effect data, and indications for recently FDA- approved pharmaceuticals and summarize their use in clinical practice.
  • Describe the impact of aging and therapies on the bone marrow microenvironment and its clinical significance on the evolution of clonal hematopoiesis.
  • Summarize the clinical needs and risk-adapted treatment strategies for myeloproliferative neoplasms.
  • List the important advances in pretransplantation risk assessment and transplant techniques for hematopoietic cell transplantation in patients with myeloid malignancies.

Target Audience

This educational activity is designed for an international audience including medical oncologists, hematologists, clinical and translational researchers, and other physicians and allied health care professionals treating patients with MDS and other bone marrow failure diseases. In addition, members of patient advocacy groups will benefit from this program.

Activity Co-Directors

Bhumika Patel, MD
Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH

Sudipto Mukherjee, MD, PhD, MPH
Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH

This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education, Cleveland Clinic’s Taussig Cancer Institute and Aplastic Anemia & MDS International Foundation.